Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Rachel K. King files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kevin Tang - $1.49M in FULC purchases and sales in the last 12 months
- Robert J. Gould - $507K in FULC purchases and sales in the last 12 months
- Alan Ezekowitz - $66K in FULC purchases and sales in the last 12 months
- Curtis Gale Oltmans - $45K in FULC purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Rachel K. King?
Rachel K. King is a corporate insider of Fulcrum Therapeutics, Inc. (FULC). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Rachel K. King last file a Form 4?
The most recent primary Form 4 on record is dated 2 July 2026, one of 5 filings going back to 2024.
